CT-202: a Dual pH-dependent Nectin-4xCD3 Bispecific T Cell Engager

Publications

Nov 7

Written by Martin Lehr

Nectin

A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results